KAIROS PHARMA LTD
KAPANYSE AMERICAN🏆 #5217 by market capEarnings Nov 13US Equity
$0.53▼ $0.01 (−1.79%)
Market closed · at closeTrack KAPA
Get earnings, price moves & breaking news on Telegram
24h▼ 1.8%
7d▼ 3.8%
14d▼ 24.7%
30d▼ 68.2%
ytd▼ 89.4%
1y▼ 93.2%
🏦Market Cap
$2M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.53 – $0.54
- 52-Week Range
- $0.52 – $8.12
- Volume (shares)
- 403
- Avg Volume (shares)
- —
- Shares Outstanding
- 3.4M
- Next Earnings
- 2026-11-13
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -0.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.90
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +34.2%
KAIROS PHARMA LTD
KAPAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▲ +137.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$3M▼ −13.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.6M▲ +34.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4M▲ +$3M YoY
StockOtter · stockotter.spaceAbout KAIROS PHARMA LTD
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.